智通财经APP获悉，周二，艾迪康控股(09860)盘中飙涨，当日收涨25.75%。消息面上，3月30日，投行富瑞金融在研报中维持艾迪康控股“买入”评级，更新目标价至7.00港元，较前一交易日收盘价3.43港元有104%的上涨空间。
该行在报告中指出，艾迪康在独立临床实验室(ICL)发展中以AI为核心发力方向。公司管理层对未来3-5年的增长前景持乐观态度，预计独立临床实验室(ICL)业务与合同研究组织(CRO，即收购的CrownBio)业务收入占比将达到50:50。2025财年，公司实现营收26亿元人民币，净利润1840万元人民币。
AI为艾迪康核心战略重点：(1)AI医生助手“小爱”嵌入细胞分析、诊断与报告流程，已服务400万患者、15万名医生，同时推出临床大语言模型“文医”，整合进诊疗全流程;(2)内部AI部署后效率显著提升，人工审核量减少90%，客户投诉量下降86%;(3)约10分钟AI辅助影像阅片：AI覆盖率超60%，累计阅片量达1300万张;此外艾迪康拥有20年临床检测数据，且通过收购CrownBio获得了丰富的临床前肿瘤数据，形成数据壁垒。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.